

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

NCT07505173

Status	RECRUITING
Phase	Phase 2
Sponsor	Tianjin Medical University Cancer Institute and Hospital
Enrollment	74 participants

Key Eligibility Criteria

Inclusion (12)

- Signed a written informed consent form prior to enrollment;
 - Aged 18-75 years;
 - Histopathologically confirmed non-small cell lung adenocarcinoma (NSCLC); EGFR gene test confirmed EGFR sensitive mutations, including exon 19 deletion (19del) and exon 21 L858R mutation (verified and confirmed by investigators at the respective study centers);
 - Brain metastasis confirmed by contrast-enhanced cranial CT/MRI; the number of brain metastatic lesions requiring local dose escalation is 1-10, with at least one measurable intracranial lesion having a diameter ≥ 10 mm; the distance between metastatic lesions and important cerebral functional areas meets radiotherapy-related requirements; at least one measurable lesion (per RECIST v1.1 criteria) confirmed by contrast-enhanced extracranial CT/PET-CT;
 - Symptomatic brain metastasis;
- ... and 7 more (see full listing online)

Exclusion (10)

- Presence of uncontrollable third space effusion (e.g., pleural effusion, ascites) that cannot be managed with drainage or other interventions;
 - Presence of multiple factors impairing oral drug administration and absorption (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.);
 - Patients who are known to be pregnant, planning pregnancy, or women of childbearing potential who refuse to adopt effective contraceptive measures throughout the study period;
 - Patients with severe concomitant diseases or those deemed ineligible for enrollment by the investigator;
 - Patients with meningeal metastasis;
- ... and 5 more (see full listing online)

Locations (1 total)

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

<https://clinicaltrials.gov/study/NCT07505173>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).